{
    "clinical_study": {
        "@rank": "33593", 
        "arm_group": {
            "arm_group_label": "High Grade Glioma", 
            "arm_group_type": "Experimental", 
            "description": "To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant,  in patients with newly diagnosed  High Grade Glioma after biopsy.total dose of 60 Gy/ 4 Gy fraction/15 fractions (BED10 84 Gy)  will prescribed to the PTV1; a total dose of  42 Gy/2.8 Gy fraction/15 fractions (BED10 53.76 Gy) will prescribed to PTV2  with SIB."
        }, 
        "brief_summary": {
            "textblock": "To evaluate safety and feasibility  of  hypofractionated IMRT in addition to chemotherapy,\n      concomitant and adjuvant,  in patients with newly diagnosed  HGGs after surgery.\n\n      Primary endpoint:  progression free survival (PFS),  Overall Survival (OS)  and Toxicity.\n\n      Secondary endpoint: to evaluate Quality of life (QoL)  of patients after surgery,\n      concomitant chemoradiotherapy and adjuvant chemotherapy through neuropsychological\n      examination."
        }, 
        "brief_title": "Hypofractionated IMRT With Temozolomide for HGG", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Glioma", 
        "condition_browse": {
            "mesh_term": "Glioma"
        }, 
        "detailed_description": {
            "textblock": "We designed a study of a hypofractionated intensity modulated radiation therapy (IMRT),\n      using VMAT RapidArc approach. The potential advantage of this approach is to deliver a more\n      selective irradiation to tumor's target with reducing dose to normal brain and to allow to\n      deliver a higher dose, optimizing the therapeutic window"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 to 70 years\n\n          -  Karnosky performance status (KPS) \u226560\n\n          -  Patients aged >70 years with KPS \u226580\n\n          -  Histopathologically confirmed of HGG\n\n          -  Estimated survival  \u2265 3 months.\n\n          -  Multifocal tumor\n\n          -  Normal liver, Kidney and bone marrow function\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Prior radiation therapy\n\n          -  KPS \u2264 60\n\n          -  Age > 70 years and KPS < 70\n\n          -  Other primary cancer\n\n          -  Pregnant women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "82", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02082119", 
            "org_study_id": "1138"
        }, 
        "intervention": {
            "arm_group_label": "High Grade Glioma", 
            "description": "Hypofractionated IMRT", 
            "intervention_name": "Hypofractionated IMRT", 
            "intervention_type": "Radiation"
        }, 
        "intervention_browse": {
            "mesh_term": "Temozolomide"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 5, 2014", 
        "location": {
            "contact": {
                "email": "piera.navarria@humanitas.it", 
                "last_name": "Piera Navarria, MD", 
                "phone": "+39-02-8224-7458"
            }, 
            "facility": {
                "address": {
                    "city": "Milan", 
                    "country": "Italy", 
                    "zip": "20100"
                }, 
                "name": "Istituto Clinico Humanitas"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "Hypofractionated IMRT (VMAT-RA) With Temozolomide for Patients With Newly Diagnosed High Grade Glioma (HGG)", 
        "overall_official": {
            "affiliation": "Humanitas Cancer Center", 
            "last_name": "Piera Navarria, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: National Bioethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival (PFS),  Overall Survival (OS)  and Toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "time of enrollment of two years"
        }, 
        "reference": {
            "PMID": "22483738", 
            "citation": "Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, Stuhr K, Kavanagh BD, Chen C. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):655-60. doi: 10.1016/j.ijrobp.2012.01.035. Epub 2012 Apr 5."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02082119"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Istituto Clinico Humanitas", 
            "investigator_full_name": "Michele Tedeschi", 
            "investigator_title": "Istituto Clinico Humanitas", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Quality of life (QoL)  of patients after surgery, concomitant chemo-radiotherapy and adjuvant chemotherapy", 
            "safety_issue": "Yes", 
            "time_frame": "two years"
        }, 
        "source": "Istituto Clinico Humanitas", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Istituto Clinico Humanitas", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}